XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration Agreements, License Agreement and Revenues - Summary of License Revenue and Development Revenue Recognized under Agreement (Detail) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 147,752 $ 140,734 $ 235,309
License Revenue [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 9,649 22,590 116,434
Development Revenue [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 18,401 24,189 70,275
Astellas Agreement [Member] | License Revenue [Member] | Europe [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 0 22,590 108,434
Astellas Agreement [Member] | Development Revenue [Member] | Japan [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 210 284 248
Astellas Agreement [Member] | Development Revenue [Member] | Europe [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 6,452 9,624 21,679
AstraZeneca Agreements [Member] | License Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue 2,649 0 0
AstraZeneca Agreements [Member] | Development Revenue [Member] | U.S./RoW and China [Member]      
Revenue Recognition Multiple Deliverable Arrangements [Line Items]      
Total revenue $ 9,473 $ 12,519 $ 48,345